Stack
CJC-1295 and Ipamorelin
The standard growth hormone pairing. Two compounds on two different receptors, which is the one combination in this category with a real mechanistic argument.
CJC-1295 is a GHRH analogue and ipamorelin is a ghrelin receptor agonist. They stimulate growth hormone release through separate pathways. That is why this pairing is the sensible one and why adding a second GHRH analogue on top adds mass rather than mechanism.
Run nightly, five days on and two off, on the reasoning that pulsatile release is what the compounds are for and continuous stimulation defeats the point.
Both raise growth hormone in human studies. Neither has been shown to produce the outcomes people run them for, and the combination has not been studied.
The schedule
Commonly run, not recommended12 weeks. Doses are what sources describe rather than what we advise — where a source gave a range we show the range instead of choosing a number inside it.
| Compound | Dose | How often | Weeks |
|---|---|---|---|
| CJC-1295Early human trialsGHRH analogue. Raises the size of the growth hormone pulse. | 100 mcg | Weekly · Mon, Tue, Wed, Thu, FriWeeknights only. The two days off are the convention for preserving pituitary responsiveness, not a finding. | 1–12 |
| IpamorelinEarly human trialsGhrelin receptor agonist. A separate pathway, which is the point of the pairing. | 200 mcg | Weekly · Mon, Tue, Wed, Thu, FriTaken at the same time as the CJC-1295, on an empty stomach. | 1–12 |
Things worth knowing
- Raising growth hormone raises IGF-1, which is a proliferative signal. Both are contraindicated in anyone with a history of cancer.
- Water retention, joint aches and carpal tunnel symptoms are the common complaints, and they are dose-dependent.
- Growth hormone opposes insulin. Anyone with impaired glucose tolerance should not run this without monitoring.
- Both compounds are prohibited in sport at all times.
- Timing on an empty stomach is the convention because food blunts the response, which is established for the mechanism rather than for these compounds specifically.
Related
Questions
- Why run both instead of one?
- This is the one combination in the category with a real mechanistic argument: the two act on different receptors, a GHRH analogue and a ghrelin-receptor agonist, so the case is that they raise growth hormone by routes that add instead of overlapping. That argument is about mechanism, not about an outcome anyone has measured in this pairing.
- Is this the same as CJC-1295 with DAC?
- No, and the difference matters more than the shared name. The DAC version has a much longer half-life and is dosed weekly; the no-DAC version is dosed daily and is what is usually meant in this pairing. Buying the wrong one produces a schedule that does not match anything written about it.
- Why at night, and why on an empty stomach?
- Both are conventions rather than findings. The reasoning is that natural growth hormone release is largest in early sleep and that food, carbohydrate especially, blunts the pulse. Neither has a human study establishing that the timing changes an outcome.
This page is educational. It describes what published research reports, not what you should do. Peptides discussed here are largely not approved for human use, and nothing on Bioalmanac is medical advice.